MX2022007844A - Tratamiento de una lesion cerebral traumatica moderada. - Google Patents
Tratamiento de una lesion cerebral traumatica moderada.Info
- Publication number
- MX2022007844A MX2022007844A MX2022007844A MX2022007844A MX2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- brain injury
- traumatic brain
- mild traumatic
- mtbi
- Prior art date
Links
- 208000007333 Brain Concussion Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 101800001586 Ghrelin Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen métodos para mitigar uno o más síntomas debilitantes de una mTBI para un paciente diagnosticado con una mTBI constante. Estos métodos comprenden administrar una cantidad efectiva de grelina o una variante de la misma durante múltiples días consecutivos después del diagnóstico de una mTBI constante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953130P | 2019-12-23 | 2019-12-23 | |
| PCT/US2020/066703 WO2021133844A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007844A true MX2022007844A (es) | 2022-09-07 |
Family
ID=76575665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007844A MX2022007844A (es) | 2019-12-23 | 2020-12-22 | Tratamiento de una lesion cerebral traumatica moderada. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230031262A1 (es) |
| EP (1) | EP4081238A4 (es) |
| JP (1) | JP2023508250A (es) |
| KR (1) | KR20220122691A (es) |
| CN (1) | CN114980915A (es) |
| AU (1) | AU2020412765A1 (es) |
| BR (1) | BR112022012365A2 (es) |
| CA (1) | CA3165738A1 (es) |
| IL (1) | IL294156A (es) |
| MX (1) | MX2022007844A (es) |
| WO (1) | WO2021133844A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113723530B (zh) * | 2021-09-02 | 2022-03-25 | 中国科学院自动化研究所 | 基于视频分析和电子心理沙盘的智能心理评估系统 |
| AU2023338304A1 (en) * | 2022-09-07 | 2025-04-10 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015073903A1 (en) * | 2013-11-15 | 2015-05-21 | Neural Analytics Inc. | Monitoring structural features of cerebral blood flow velocity for diagnosis of neurological conditions |
| US9119832B2 (en) * | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CA2961889A1 (en) * | 2014-08-19 | 2016-02-25 | Oxeia Biopharmaceuticals, Inc. | Methods of treating mild brain injury |
| US20180028617A1 (en) * | 2015-02-19 | 2018-02-01 | The Regents Of The University Of California | Methods of treating mild brain injury and post-traumatic stress disorder |
| AU2016229848A1 (en) * | 2015-03-09 | 2017-10-26 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
-
2020
- 2020-12-22 EP EP20905518.5A patent/EP4081238A4/en active Pending
- 2020-12-22 JP JP2022564096A patent/JP2023508250A/ja active Pending
- 2020-12-22 CA CA3165738A patent/CA3165738A1/en active Pending
- 2020-12-22 CN CN202080092650.7A patent/CN114980915A/zh active Pending
- 2020-12-22 BR BR112022012365A patent/BR112022012365A2/pt not_active Application Discontinuation
- 2020-12-22 MX MX2022007844A patent/MX2022007844A/es unknown
- 2020-12-22 KR KR1020227025653A patent/KR20220122691A/ko not_active Withdrawn
- 2020-12-22 AU AU2020412765A patent/AU2020412765A1/en active Pending
- 2020-12-22 IL IL294156A patent/IL294156A/en unknown
- 2020-12-22 US US17/787,848 patent/US20230031262A1/en active Pending
- 2020-12-22 WO PCT/US2020/066703 patent/WO2021133844A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN114980915A (zh) | 2022-08-30 |
| AU2020412765A1 (en) | 2022-07-14 |
| CA3165738A1 (en) | 2021-07-01 |
| WO2021133844A1 (en) | 2021-07-01 |
| JP2023508250A (ja) | 2023-03-01 |
| BR112022012365A2 (pt) | 2022-08-30 |
| KR20220122691A (ko) | 2022-09-02 |
| IL294156A (en) | 2022-08-01 |
| EP4081238A1 (en) | 2022-11-02 |
| EP4081238A4 (en) | 2023-08-30 |
| US20230031262A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| NZ751690A (en) | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves | |
| CA3114021C (en) | METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE | |
| PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| MY162067A (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| IL284414A (en) | Methods and preparations for the treatment of Fabry disease | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MX2019012086A (es) | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2022007844A (es) | Tratamiento de una lesion cerebral traumatica moderada. | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| MX377438B (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| MX2018007152A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. | |
| WO2015130790A3 (en) | Salts of heterocyclic modulators of hif activity for treatment of disease | |
| PH12021552741A1 (en) | Solid forms of a glyt1 inhibitor | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| WO2019157527A3 (en) | Methods related to parkinson's disease and synucleinopathies | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| IL289592A (en) | Methods for diagnosing the effectiveness of treatment against you | |
| GB202011522D0 (en) | Neuromodulation for the treatment of circulatory system diseases | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы |